Cytokinetics (Cytokinetics) Change In Inventory : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Cytokinetics Change In Inventory?

Cytokinetics's change in inventory for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Cytokinetics's inventory stayed the same from Sep. 2023 to Dec. 2023 .

Cytokinetics's change in inventory for the fiscal year that ended in Dec. 2023 was $0.00 Mil. It means Cytokinetics's inventory stayed the same from Dec. 2022 to Dec. 2023 .

Cytokinetics's Total Inventories for the quarter that ended in Dec. 2023 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Cytokinetics's Days Inventory for the quarter that ended in Dec. 2023 was 0.00.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Cytokinetics's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.00.

Cytokinetics Change In Inventory Historical Data

The historical data trend for Cytokinetics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytokinetics Change In Inventory Chart

Cytokinetics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Get a 7-Day Free Trial

Cytokinetics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Cytokinetics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Cytokinetics (NAS:CYTK) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Cytokinetics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	84.976	*	365 / 4
	=	0.00

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Cytokinetics's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	84.976	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Cytokinetics's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	1.672
	=	0.00

Cytokinetics Change In Inventory Related Terms

Thank you for viewing the detailed overview of Cytokinetics's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytokinetics (Cytokinetics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytokinetics Inc (NAS:CYTK) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

KK3A:Germany

Address

350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.cytokinetics.com

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Executives

Robert I Blum	officer: EVP, Corp. Development & CBO	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John T Henderson	director	320 WAKARA WAY, SALT LAKE CITY UT 84108
Fady Ibraham Malik	officer: SVP Research & Early Dev	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Wendall Wierenga	director	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Muna Bhanji	director	C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Robert Wong	officer: VP, Chief Accounting Officer	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Ching Jaw	officer: SVP Finance & CFO	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Sandford D Smith	director	C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
B Lynne Parshall	director	2855 GAZELLE COURT, CARLSBAD CA 92010
Santo J Costa	director
Kaye Edward M. Md	director	3450 MONTE VILLA PARKWAY, BOTHELL WA 98011
Robert Arthur Harrington	director	C/O CYTOKINETICS, INCORPORATED, 350 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Mark A Schlossberg	officer: SVP - Legal & General Counsel	C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
David Cragg	officer: V.P., Human Resources	280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
L Patrick Gage	director	C/O NEOSE TECHNOLOGIES, 102 WITMER RD, HORSHAM PA 19044